Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT05683470 No longer available - Clinical trials for Expanded Access in Pancreatic Cancer

Expanded Access RBS2418 Treatment

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.

NCT ID: NCT04137822 No longer available - Pancreatic Cancer Clinical Trials

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

Start date: n/a
Phase:
Study type: Expanded Access

An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.

NCT ID: NCT04087889 No longer available - Pancreatic Cancer Clinical Trials

Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer

Start date: n/a
Phase:
Study type: Expanded Access

The drug for this submission is Hope Biosciences' allogeneic, first blood relative, adipose-derived culture-expanded mesenchymal stem cells (HB-adMSCs) for the treatment of a single patient with Pancreatic Cancer (PC). PC is an extremely infiltrative neoplasm that usually presents with vascular and perineural invasion in surgically resected tumors. Metastases to lymph nodes, liver and distant sites are all very common. Its incidence has markedly increased over the past several decades and ranks as the fourth leading cause of cancer death in the United States. Despite the high mortality rate associated with pancreatic cancer, its etiology is poorly understood. PC patients experience physiological symptoms such as anemia, ascites, severe fatigue, pain, cachexia, weakness, insomnia, confusion, and memory loss. The aggressive nature of PC leads to rapid deterioration of patients' quality of life and diminished ability to participate in treatment.

NCT ID: NCT03554434 No longer available - Breast Cancer Clinical Trials

An Expanded Access Program for AM0010 (Pegilodecakin)

Start date: n/a
Phase:
Study type: Expanded Access

This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.

NCT ID: NCT02449135 No longer available - Pancreatic Cancer Clinical Trials

Nano Drug Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Carcinoma

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to evaluate the safety and efficacy of nano drug interventional therapy using digital subtraction angiography(DSA) for pancreatic cancer. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.